341 related articles for article (PubMed ID: 11708878)
21. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
22. Cell-type-specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression.
Smith-Arica JR; Morelli AE; Larregina AT; Smith J; Lowenstein PR; Castro MG
Mol Ther; 2000 Dec; 2(6):579-87. PubMed ID: 11124058
[TBL] [Abstract][Full Text] [Related]
23. Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector.
Folliot S; Briot D; Conrath H; Provost N; Cherel Y; Moullier P; Rolling F
J Gene Med; 2003 Jun; 5(6):493-501. PubMed ID: 12797114
[TBL] [Abstract][Full Text] [Related]
24. Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR.
Jiang L; Rampalli S; George D; Press C; Bremer EG; O'Gorman MR; Bohn MC
Gene Ther; 2004 Jul; 11(13):1057-67. PubMed ID: 15152187
[TBL] [Abstract][Full Text] [Related]
25. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
26. Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector.
Lena AM; Giannetti P; Sporeno E; Ciliberto G; Savino R
J Gene Med; 2005 Aug; 7(8):1086-96. PubMed ID: 15772935
[TBL] [Abstract][Full Text] [Related]
27. Homogeneity and long-term stability of tetracycline-regulated gene expression with low basal activity by using the rtTA2S-M2 transactivator and insulator-flanked reporter vectors.
Qu Z; Thottassery JV; Van Ginkel S; Manuvakhova M; Westbrook L; Roland-Lazenby C; Hays S; Kern FG
Gene; 2004 Feb; 327(1):61-73. PubMed ID: 14960361
[TBL] [Abstract][Full Text] [Related]
28. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
29. In vivo transgene expression using an adenoviral tetracycline-regulated system with neuron-specific enolase promoter.
Bhattacharjee AK; Ueyama T; Kondoh T; Hayashi S; Abouelfetouh A; Sakai N; Saito N; Kohmura E
Biochem Biophys Res Commun; 2004 May; 317(4):1144-8. PubMed ID: 15094388
[TBL] [Abstract][Full Text] [Related]
30. Tetracycline-inducible transgene expression mediated by a single AAV vector.
Chtarto A; Bender HU; Hanemann CO; Kemp T; Lehtonen E; Levivier M; Brotchi J; Velu T; Tenenbaum L
Gene Ther; 2003 Jan; 10(1):84-94. PubMed ID: 12525840
[TBL] [Abstract][Full Text] [Related]
31. Stringent and reproducible tetracycline-regulated transgene expression by site-specific insertion at chromosomal loci with pre-characterised induction characteristics.
Brough R; Papanastasiou AM; Porter AC
BMC Mol Biol; 2007 May; 8():30. PubMed ID: 17493262
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.
Hedlund TE; Meech SJ; Srikanth S; Kraft AS; Miller GJ; Schaack JB; Duke RC
Cell Death Differ; 1999 Feb; 6(2):175-82. PubMed ID: 10200564
[TBL] [Abstract][Full Text] [Related]
33. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression.
Hyer ML; Sudarshan S; Schwartz DA; Hannun Y; Dong JY; Norris JS
Cancer Gene Ther; 2003 Apr; 10(4):330-9. PubMed ID: 12679806
[TBL] [Abstract][Full Text] [Related]
34. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
35. Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system.
Block A; Puls F; Müller J; Milasinovic D; Igelmann D; Schäfer P; Kupfermann N; Schmoldt A; Ameis D; Greten H
J Gene Med; 2003 Mar; 5(3):190-200. PubMed ID: 12666185
[TBL] [Abstract][Full Text] [Related]
36. Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system.
Watsuji T; Okamoto Y; Emi N; Katsuoka Y; Hagiwara M
Biochem Biophys Res Commun; 1997 May; 234(3):769-73. PubMed ID: 9175791
[TBL] [Abstract][Full Text] [Related]
37. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.
Pramudji C; Shimura S; Ebara S; Yang G; Wang J; Ren C; Yuan Y; Tahir SA; Timme TL; Thompson TC
Clin Cancer Res; 2001 Dec; 7(12):4272-9. PubMed ID: 11751529
[TBL] [Abstract][Full Text] [Related]
38. Autoregulated multicistronic expression vectors provide one-step cloning of regulated product gene expression in mammalian cells.
Fussenegger M; Moser S; Mazur X; Bailey JE
Biotechnol Prog; 1997; 13(6):733-40. PubMed ID: 9413131
[TBL] [Abstract][Full Text] [Related]
39. Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice.
Dumortier J; Schönig K; Oberwinkler H; Löw R; Giese T; Bujard H; Schirmacher P; Protzer U
Gene Ther; 2005 Apr; 12(8):668-77. PubMed ID: 15647761
[TBL] [Abstract][Full Text] [Related]
40. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
